BridgeBio Pharma (NASDAQ:BBIO) Given New $50.00 Price Target at JPMorgan Chase & Co.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & Co. from $44.00 to $50.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a […]
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & Co. from $44.00 to $50.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a […]
